Literature DB >> 28536143

Aurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP.

Sukumar Sarkar1, David L Brautigan2, James M Larner3.   

Abstract

Reducing the levels of the androgen receptor (AR) is one of the most viable approaches to combat castration-resistant prostate cancer. Previously, we observed that proteasomal-dependent degradation of AR in response to 2-methoxyestradiol (2-ME) depends primarily on the E3 ligase C-terminus of HSP70-interacting protein (STUB1/CHIP). Here, 2-ME stimulation activates CHIP by phosphorylation via Aurora kinase A (AURKA). Aurora A kinase inhibitors and RNAi knockdown of Aurora A transcript selectively blocked CHIP phosphorylation and AR degradation. Aurora A kinase is activated by 2-ME in the S-phase as well as during mitosis, and phosphorylates CHIP at S273. Prostate cancer cells expressing an S273A mutant of CHIP have attenuated AR degradation upon 2-ME treatment compared with cells expressing wild-type CHIP, supporting the idea that CHIP phosphorylation by Aurora A activates its E3 ligase activity for the AR. These results reveal a novel 2-MEAurora A→CHIP→AR pathway that promotes AR degradation via the proteasome that may offer novel therapeutic opportunities for prostate cancer. Mol Cancer Res; 15(8); 1063-72. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28536143      PMCID: PMC5697428          DOI: 10.1158/1541-7786.MCR-17-0062

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  CHIP E3 ligase regulates mammalian senescence by modulating the levels of oxidized proteins.

Authors:  Christina Sisoula; Efstathios S Gonos
Journal:  Mech Ageing Dev       Date:  2011-04-12       Impact factor: 5.432

2.  The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation.

Authors:  Claudia Esser; Martin Scheffner; Jörg Höhfeld
Journal:  J Biol Chem       Date:  2005-05-23       Impact factor: 5.157

3.  The co-chaperone CHIP is induced in various stresses and confers protection to cells.

Authors:  Priyanka Dikshit; Nihar Ranjan Jana
Journal:  Biochem Biophys Res Commun       Date:  2007-04-11       Impact factor: 3.575

4.  C-terminus of heat shock cognate 70 interacting protein increases following stroke and impairs survival against acute oxidative stress.

Authors:  Jeannette N Stankowski; Stephanie L H Zeiger; Evan L Cohen; Donald B DeFranco; Jiyang Cai; BethAnn McLaughlin
Journal:  Antioxid Redox Signal       Date:  2010-12-02       Impact factor: 8.401

5.  Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but Not HIF-2alpha.

Authors:  Weibo Luo; Jun Zhong; Ryan Chang; Hongxia Hu; Akhilesh Pandey; Gregg L Semenza
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

6.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Kristan A Meetze; Suresh K Balani; Olga Burenkova; Wei Chen; Katherine M Galvin; Kara M Hoar; Jessica J Huck; Patrick J LeRoy; Emily T Ray; Todd B Sells; Bradley Stringer; Stephen G Stroud; Tricia J Vos; Gabriel S Weatherhead; Deborah R Wysong; Mengkun Zhang; Joseph B Bolen; Christopher F Claiborne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-23       Impact factor: 11.205

7.  Targeting Aurora kinases for the treatment of prostate cancer.

Authors:  Edmund Chun Yu Lee; Anna Frolov; Rile Li; Gustavo Ayala; Norman M Greenberg
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

Review 8.  Aurora kinase inhibitors: progress towards the clinic.

Authors:  Madhu Kollareddy; Daniella Zheleva; Petr Dzubak; Pathik Subhashchandra Brahmkshatriya; Martin Lepsik; Marian Hajduch
Journal:  Invest New Drugs       Date:  2012-02-18       Impact factor: 3.850

Review 9.  The aurora kinases in cell cycle and leukemia.

Authors:  B Goldenson; J D Crispino
Journal:  Oncogene       Date:  2014-03-17       Impact factor: 9.867

Review 10.  Non-centrosomal TPX2-Dependent Regulation of the Aurora A Kinase: Functional Implications for Healthy and Pathological Cell Division.

Authors:  Georgina Garrido; Isabelle Vernos
Journal:  Front Oncol       Date:  2016-04-15       Impact factor: 6.244

View more
  14 in total

1.  Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.

Authors:  Shidong Lv; Qiong Song; Guang Chen; Erdong Cheng; Wei Chen; Ryan Cole; Zeyu Wu; Laura E Pascal; Ke Wang; Peter Wipf; Joel B Nelson; Qiang Wei; Wenhua Huang; Zhou Wang
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

Review 2.  Functional roles of E3 ubiquitin ligases in prostate cancer.

Authors:  Yiting Zhao; Jinyun Li; Jun Chen; Meng Ye; Xiaofeng Jin
Journal:  J Mol Med (Berl)       Date:  2022-07-11       Impact factor: 5.606

Review 3.  The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.

Authors:  Liuxun Li; Jiangli Xu
Journal:  Clin Transl Oncol       Date:  2022-10-06       Impact factor: 3.340

4.  Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.

Authors:  Fengyi Mao; Yifan Kong; Jinghui Liu; Xiongjian Rao; Chaohao Li; Kristine Donahue; Yanquan Zhang; Katelyn Jones; Qiongsi Zhang; Wei Xu; Xiaoqi Liu
Journal:  Prostate       Date:  2022-03-24       Impact factor: 4.104

Review 5.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

6.  The expression of AURKA is androgen regulated in castration-resistant prostate cancer.

Authors:  Kati Kivinummi; Alfonso Urbanucci; Katri Leinonen; Teuvo L J Tammela; Matti Annala; William B Isaacs; G Steven Bova; Matti Nykter; Tapio Visakorpi
Journal:  Sci Rep       Date:  2017-12-21       Impact factor: 4.379

Review 7.  Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.

Authors:  Ruijuan Du; Chuntian Huang; Kangdong Liu; Xiang Li; Zigang Dong
Journal:  Mol Cancer       Date:  2021-01-15       Impact factor: 27.401

8.  Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.

Authors:  Emmanuel S Antonarakis; Andrew J Armstrong; Jun Luo; Changxue Lu; Landon C Brown
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-03-05       Impact factor: 5.554

Review 9.  Loss and revival of androgen receptor signaling in advanced prostate cancer.

Authors:  Nicolò Formaggio; Mark A Rubin; Jean-Philippe Theurillat
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

10.  AR ubiquitination induced by the curcumin analog suppresses growth of temozolomide-resistant glioblastoma through disrupting GPX4-Mediated redox homeostasis.

Authors:  Tzu-Chi Chen; Jian-Ying Chuang; Chiung-Yuan Ko; Tzu-Jen Kao; Pei-Yu Yang; Chun-Hui Yu; Ming-Sheng Liu; Siou-Lian Hu; Yu-Ting Tsai; Hardy Chan; Wen-Chang Chang; Tsung-I Hsu
Journal:  Redox Biol       Date:  2019-12-26       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.